Each year, 795,000 AMERICANS experience a stroke.¹

~610,000 are new strokes
~185,000 are recurrent strokes¹

ABOUT CRYPTOGENIC STROKE¹⁻⁷
- Each year, approximately 795,000 Americans experience a stroke—610,000 of which are first events and 185,000 of which are recurrent stroke events.¹
- In 2011, stroke caused roughly one of every 20 deaths in the United States.¹
- The most common type of stroke is called an “ischemic stroke,” which affects about 690,000 Americans annually and is a result of an obstruction within a blood vessel supplying blood to the brain.¹
- If the cause of an ischemic stroke cannot be determined, the stroke is called “cryptogenic,” or a stroke of unknown cause.¹
- Cryptogenic strokes account for approximately 20 to 40 percent of ischemic strokes in the majority of modern stroke registries and databases.¹⁻⁷

ABOUT ATRIAL FIBRILLATION⁸
- Atrial fibrillation (also known as AF or “a-fib”) is a common cardiac condition defined by irregular or rapid heartbeats.
- Failure to recognize and treat AF can lead to strokes as patients with AF are five times more likely to have a stroke.

ABOUT CONTINUOUS, LONG-TERM CARDIAC MONITORING
- Undiagnosed AF is believed to be responsible for a significant portion of cryptogenic strokes.¹⁻⁷
- However, because AF often has no symptoms and may occur infrequently, it may not be detected by conventional monitoring techniques such as in-hospital monitoring, electrocardiography, or traditional ambulatory cardiac monitors (e.g., Holter).⁹⁻¹²
- Unlike conventional monitoring methods, continuous, long-term cardiac monitoring devices, such as the Reveal LINQ™ Insertable Cardiac Monitor (ICM), automatically and continuously detect and record abnormal heart rhythms for up to three years.¹³
- Detecting AF allows physicians to change a patient's medical therapy (e.g., from anti-platelet to oral anticoagulation per guidelines) to potentially help reduce his/her risk of having a second stroke.¹⁴⁻¹⁵
ABOUT THE MEDTRONIC REVEAL LINQ™ ICM SYSTEM

- Cleared by the U.S. Food & Drug Administration (FDA) in February 2014, the Reveal LINQ ICM is the newest generation Reveal ICM and the smallest cardiac monitor available (~1 cc, or one-third the size of a AAA battery).
- Common uses include monitoring syncpe patients for potential episodes of bradycardia/asystole, monitoring cryptogenic stroke patients for possible episodes of AF, and monitoring patients suffering from intermittent chest palpitations for potential episodes of atrial or ventricular arrhythmias.
- The Reveal LINQ ICM is placed under the skin of the chest, and its battery allows for up to three years of monitoring.
- Additionally, the device communicates wirelessly with a patient bedside monitor that uploads device data to the Medtronic CareLink™ network.

SUPPORTING EVIDENCE

- The CRYSTAL AF (CRYptogenic STroke And underLying Atrial Fibrillation) study, published in The New England Journal of Medicine, found that continuous cardiac monitoring with the Reveal™ ICM was superior to standard care (SoC) at detecting AF in patients who had a cryptogenic stroke, detecting AF at a rate seven times higher than SoC monitoring at 12 months.16
- A study presented at the American Heart Association’s 2015 International Stroke Conference found that the Reveal LINQ ICM detected AF in everyday clinical practice at a much higher rate (37 percent relative increase) than was found in the CRYSTAL AF study, suggesting that AF may go undetected at an even greater rate than previously thought.17
- A separate new analysis presented at the same meeting demonstrated that long-term cardiac monitoring is a cost-effective method of detecting AF in cryptogenic stroke patients to potentially prevent a recurrent stroke.18
- Research presented at the 2016 American Academy of Neurology Annual Meeting showed that in a real-world population of cryptogenic stroke patients, 72 percent of AF patients would have gone undiagnosed if cardiac monitoring had been limited to 30 days.19

CRYSTAL-AF study results

<table>
<thead>
<tr>
<th>Months since randomization</th>
<th>Atrial Fibrillation Detected (% of patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.4%</td>
</tr>
<tr>
<td>6</td>
<td>2%</td>
</tr>
<tr>
<td>12</td>
<td>12.4%</td>
</tr>
<tr>
<td>18</td>
<td>6.9%</td>
</tr>
<tr>
<td>24</td>
<td>7.3X</td>
</tr>
<tr>
<td>30</td>
<td>6.4X</td>
</tr>
<tr>
<td>36</td>
<td>30%</td>
</tr>
<tr>
<td>Control</td>
<td>8.8X</td>
</tr>
</tbody>
</table>

Control group had 8.8X more AF detected at 36 months.

Research presented at the 2016 American Academy of Neurology Annual Meeting showed that in a real-world population of cryptogenic stroke patients, 72 percent of AF patients would have gone undiagnosed if cardiac monitoring had been limited to 30 days.
Abstract

Insertable Cardiac Monitors. Abstract presented at: American Academy of Neurology’s Annual Meeting; 2016 April 16-20; Vancouver, BC, Canada.

13. Refer to the Reveal LINQICM Clinician Manual for usage parameters.

Medtronic MyCareLink Patient Monitor, Medtronic CareLink Network and CareLink Mobile Application

Intended Use

The Medtronic MyCareLink Patient Monitor and CareLink Network are indicated for use in the transfer of patient data from some Medtronic implantable cardiac devices based on physician instructions and as described in the product manual. The CareLink Mobile Application is intended to provide current CareLink Network customers access to CareLink Network data via a mobile device for their convenience. The CareLink Mobile Application is not replacing the full workstation, but can be used to review patient data when a physician does not have access to a workstation. These products are not a substitute for appropriate medical attention in the event of an emergency and should only be used as directed by a physician. CareLink Network availability and mobile device accessibility may be unavailable at times due to maintenance or updates, or due to coverage being unavailable in your area. Mobile device access to the Internet is required and subject to coverage availability. Standard text message rates apply.

Contraindications

There are no known contraindications.

Warnings and Precautions

The MyCareLink Patient Monitor must only be used for interrogating compatible Medtronic implantable devices.

See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events. For further information, please call Medtronic at 1 (800) 328-2518 and/or consult Medtronic’s website at www.medtronic.com.

Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.

Medtronic

710 Medtronic Parkway

Minneapolis, MN 55432-5604

Toll-free: 1 (800) 328-2518

USA

Tel: (763) 514-4000

Fax: (763) 514-4879

medtronic.com